Basis: FMP quote market capitalization / four-quarter operating cash flow less absolute capital expenditures. Source: stored company filings and market data; unavailable inputs remain N/A.
The Price/FCF ratio is N/A as of 2026-10-06T16:03:42.162Z.
Calculation as of: 2026-10-06T16:03:42.162Z.
Quote observation: 2026-10-06T16:00:05.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: fa669979e2b3f995ef920df13c3a539cab2f3704a4556e475e3dd75e53b0e3a2
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
PRICE/FCF RATIO
N/A
Kestra Medical Technologies, Ltd.
Market Cap
$1.61B
Price/FCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$1.63B
Price/FCF Ratio
N/A
TTM Avg
13.72
3Y Avg
19.67
5Y Avg
19.67
Market Cap
$1.65B
Price/FCF Ratio
396.43
TTM Avg
377.27
3Y Avg
377.27
5Y Avg
377.27
| NAME | MARKET CAP | PRICE/FCF RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Kestra Medical Technologies, Ltd. (KMTS) | $1.61B | N/A | N/A | N/A | N/A |
| ANI Pharmaceuticals, Inc. (ANIP)vs › | $1.63B | N/A | 13.72 | 19.67 | 19.67 |
| Omnicell, Inc. (OMCL)vs › | $1.60B | 11.32 | 16.59 | 13.31 | 50.27 |
| Ocular Therapeutix, Inc. (OCUL)vs › | $1.63B | N/A | N/A | N/A | N/A |
| Alphatec Holdings, Inc. (ATEC)vs › | $1.65B | 396.43 | 377.27 | 377.27 | 377.27 |
| Innoviva, Inc. (INVA)vs › | $1.54B | 8.19 | 9.29 | 8.77 | 7.33 |
| uniQure N.V. (QURE)vs › | $1.54B | N/A | 3.72 | 3.76 | 3.76 |
| Nutex Health, Inc. (NUTX)vs › | $1.54B | 5.61 | 5.25 | 8.94 | 38.84 |
| Personalis, Inc. (PSNL)vs › | $1.70B | N/A | N/A | N/A | N/A |
| Eton Pharmaceuticals, Inc. (ETON)vs › | $1.51B | 102.81 | 59.64 | 44.52 | 43.50 |
P/FCF Ratio
N/A
FCF Yield
N/A
P/FCF measures market price relative to free cash flow per share. Free cash flow is operating cash flow after capital expenditures.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
